{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:53Z","timestamp":1786988153080,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002573","name":"Yonsei University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejps.2023.106402","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T12:48:17Z","timestamp":1675687697000},"page":"106402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population"],"prefix":"10.1016","volume":"184","author":[{"given":"Yesong","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwoo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-1143","authenticated-orcid":false,"given":"Kyungsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106402_bib0001","series-title":"Leflunomide, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.ejps.2023.106402_bib0002","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.62.10.944","article-title":"Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study","volume":"62","author":"Aletaha","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2023.106402_bib0003","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1124\/dmd.109.027482","article-title":"Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis","volume":"37","author":"Bohanec Grabar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106402_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.2005.02415.x","article-title":"Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis","volume":"60","author":"Chan","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106402_bib0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/kes321","article-title":"Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen","volume":"52","author":"Cutolo","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejps.2023.106402_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-05644-7","article-title":"Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels","volume":"12","author":"Fajardo-Robledo","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2023.106402_bib0007","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.2003.014217","article-title":"Dose escalation of leflunomide (LEF) to 40\u00a0mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF","volume":"63","author":"Fiehn","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2023.106402_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clpt.2004.11.010","article-title":"Effect of nonmem minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: a case study","volume":"77","author":"Gastonguay","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106402_bib0009","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2023.106402_bib0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/psp4.46","article-title":"Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients","volume":"4","author":"Hopkins","year":"2015","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106402_bib0011","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1038\/s41598-021-85174-w","article-title":"Enteric reabsorption processes and their impact on drug pharmacokinetics","volume":"11","author":"Ibarra","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2023.106402_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00228-010-0916-0","article-title":"Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level","volume":"67","author":"Kim","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106402_bib0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","article-title":"Maintenance of remission with leflunomide in Wegener's granulomatosis","volume":"43","author":"Metzler","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejps.2023.106402_bib0014","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase I1 study","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthrit. Rheumat."},{"key":"10.1016\/j.ejps.2023.106402_bib0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106402_bib0016","first-page":"27","article-title":"Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group","volume":"53","author":"Rozman","year":"1998","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.ejps.2023.106402_bib0017","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","article-title":"Clinical pharmacokinetics of leflunomide","volume":"41","author":"Rozman","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106402_bib0018","unstructured":"Sanofi-Aventis, 1998. ARAVA(leflunomide) [FDA label] U.S. Food and Drug Administration website."},{"key":"10.1016\/j.ejps.2023.106402_bib0019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10928-005-0049-8","article-title":"Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis","volume":"32","author":"Shi","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2023.106402_bib0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.11452","article-title":"Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients","volume":"49","author":"Siva","year":"2003","journal-title":"Arthrit. Rheum.-Arthr."},{"key":"10.1016\/j.ejps.2023.106402_bib0021","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/00498254.2018.1463117","article-title":"On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe","volume":"49","author":"Soulele","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2023.106402_bib0022","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.2004.025205","article-title":"Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis","volume":"64","author":"van Roon","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2023.106402_bib0023","unstructured":"W. Weber, L.H., 1997. Use of a Population Approach to the Development of Leflunomide: A New Disease-Modifying Drug in the Treatment of Rheumatoid Arthritis. Hoechst Marion Roussel. COST B1 medicine, Geneva, pp. 239\u2013244."},{"key":"10.1016\/j.ejps.2023.106402_bib0024","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P","article-title":"Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis","volume":"42","author":"Weinblatt","year":"1999","journal-title":"Arthrit. Rheum."},{"key":"10.1016\/j.ejps.2023.106402_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejps.2023.106402_bib0026","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00007890-200202150-00008","article-title":"Experiences with leflunomide in solid organ transplantation","volume":"73","author":"Williams","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ejps.2023.106402_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.05.020","article-title":"A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus","volume":"136","author":"Yao","year":"2019","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:04:53Z","timestamp":1760529893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0928098723000337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106402","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106402"}}